Literature DB >> 7276991

Xenograft of human malignant glial tumors into brains of nude mice. A histopatholgical study.

B C Horten, G A Basler, W R Shapiro.   

Abstract

Sixteen of 21 human malignant glial tumors were successfully heterotransplanted into the brains of nude mice, and one other was transplanted into the brain after prior subcutaneous heterotransplantation. Most xenografts grew preferentially as diffusely infiltrating tumors within hemispheric white matter, generally sparing cortex and deep gray matter. The heterogeneity of most in vivo human tumors gave way to a tumor of generally uniform cell type while growing in nude mice. From six human tumors, all glioblastomas, there emerged histologic patterns or cell forms that were not evident in the original tumor. Tumors from 15 patients were treated with standard chemotherapeutic agents while growing in nude mouse brains. The most common morphologic change induced in tumors by several agents was a distinctive giant cell change characterized by large bizarre nuclei and abundant cytoplasm. It is concluded that the human brain-tumor-nude-mouse xenograft model offers morphological parallels with the clinical situation, but selects for growth only some of the many subpopulations of the human tumor. Such selection imposes restriction on the clinical inferences that may be drawn from this model.

Entities:  

Mesh:

Year:  1981        PMID: 7276991     DOI: 10.1097/00005072-198109000-00002

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  16 in total

1.  Reconstituted basement membrane (matrigel) enhances the growth of human glioma cell lines in nude mice.

Authors:  A Akbasak; C C Toevs; D W Laske
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 3.  Mitogens as motogens.

Authors:  M R Chicoine; D L Silbergeld
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 4.  Invasiveness of primary brain tumors.

Authors:  O D Laerum; R Bjerkvig; S K Steinsvåg; L de Ridder
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

5.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

Review 6.  Image-guided 1H NMR spectroscopical and histological characterization of a human brain tumor model in the nude rat; a new approach to monitor changes in tumor metabolism.

Authors:  H J Bernsen; A Heerschap; A J van der Kogel; J J van Vaals; M J Prick; E F Poels; J Meyer; J A Grotenhuis
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

7.  Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model.

Authors:  M Wiranowska; A A Gonzalvo; S Saporta; O R Gonzalez; L D Prockop
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

8.  Current brain tumour models with particular consideration of the transplantation techniques. Outline of literature and personal preliminary results.

Authors:  B Rama; O Spoerri; M Holzgraefe; H D Mennel
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

Review 9.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

10.  Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Authors:  Arman Jahangiri; Michael De Lay; Liane M Miller; W Shawn Carbonell; Yu-Long Hu; Kan Lu; Maxwell W Tom; Jesse Paquette; Taku A Tokuyasu; Sean Tsao; Roxanne Marshall; Arie Perry; Kirsten M Bjorgan; Myriam M Chaumeil; Sabrina M Ronen; Gabriele Bergers; Manish K Aghi
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.